Thank you, everyone. good and Justin day
me today Let with our program. begin Epidiolex
seizures in Lennox-Gastaut completed in have the Europe and U.S. of the treatment for Epidiolex We both syndrome regulatory and with associated now submissions Dravet syndrome.
you goal period. FDA by been year, likely an June XX reflects expedited this know, review a assigned date which of As PDUFA we decision have
have also regarding held is communication Committee We FDA the be received quarter. an from in Advisory to expected the which Meeting second
in Our team of to is the and forward meeting expand preparing we look awareness for this to continuing Epidiolex form. this
a and are manufacturing these is manner. in clinical process inspections, proceeding standard the scheduled the and Regarding
pivotal tuberous Epidiolex other of are of fourth a of third part spasms. the this expected study are In the part recruiting safety this first patients addition our in this Phase epilepsy also of we year into results we whether in results To commenced complex, which Dravet trial indication involving with pursuing this expected to we and first are the into currently of indications. are will our end, regarding have of X/X for will efficacy target infantile of inform part study LGS syndrome, single from to spasms the Data These in quarter proceed we sclerosis this and two-part development study, XX expand the X indication. decision QX. and infantile Phase in
randomized evaluating Beyond this completed patients has with patients. or in trial. CBDV Epidiolex, add-on as with therapy inadequately XXX we Recruitment for conducting controlled in Phase X seizures adult a randomized we Cannabidivarin are placebo-controlled which trial double-blind focal are
become in available expecting communicate top this study. will to for trial release. which press this been this a we quarter, are our results what asked We are expectations I line from have
clinical pivotal terms the of is validate anticonvulsant support lot will preclinical to the data, the development. concept a and The this CBDV phase and of to outcomes most of that will anticipate While are I to that and not statistical yet outcomes seizure CBDV. agent learn have we as in order to in our an remind We of molecule program has proceeding as also in significance we data of such but you a to study, of a efficacy the utility of into preclinical will reduction about pharmacology our offers hypothesis promising a study, proof such this POC for see interested the in clinical outcomes CBDV the on regarding has cognitional information be us led CBDV. totality pursue shown behavior, which critical development development small of started related field trial expected the investigator-led access the disorders. patients is of in A in XX spectrum the autism in to study placebo-controlled commence in investigator-led autism half autism first in an XXXX. U.S., also has while with inform pharmacokinetics expanded
Rett In almost including that exclusively orphan syndrome addition, non-inherited, the of walk, eat, and the to designation affecting breathe hand received speak, severe leads is Rett we their ability evaluation while girls in condition easily. have Rett to aspect in are rare and life for near we CBDV impairments which of of hallmark is awake. the even of occurs neurodevelopmental nearly progressing from FDA. drug repetitive The movements disorder a the postnatal, genetic, syndrome, constant every child's syndrome
in followed expect placebo We Phase by a of the second quarter. trial commence label controlled X quarter an to start company in investigator-sponsored Rett the trial in open sponsored third the
GW from As we ownership commercialization recovered full development has reported, partner of and U.S. former licensing recently rights the a Sativex. now to
Europe associated field new, approved for the this reminder, that within of product in believe As used a in stage, U.S. the U.S. developed the by exciting, countries with neurology. we is several represents asset ago, their pipeline to now and opportunity outside years being spasticity patients and an market manage sclerosis. numerous late the multiple and this We product de-risked
the in this a exciting modified may new Indeed, consistent already pivotal scale of the its placebo-controlled demonstrated required profile NDA results. the clinically by that that that of and which positive similar treatment-resistant the Sativex Ashworth in MS spasticity. previous We was trial trials. expect additional Paris. scale U.S. reinforced from In effects those national prior safety seen at last an showing would be this trial Sativex be trial key and This in an provides completed, the September primary endpoints efficacy spasticity improvements trial, ECTRIMS very that submission secondary further believe to year data on including presented design study to with relevant was in in in of MS met
currently this a year. planning activities FDA We with are later commencing consultation to view with the development
analysis patients perform observations recurrent previously to this pursuing into and Phase promising of to ensure data opportunity continued substantiated pipeline combination program. are a initial from our the that also to placebo-controlled X on advancing with of We a prior development glioblastoma CBD in detailed THC clinical study a completed clinical our and pivotal
to data this was results keeping in and look that on from you last meeting presented where compared study I the Thank will ASCO impressive forward recall presented updated our progress. you at to group placebo. year's the You survival we future active
on Let to me Julian provide commercial the ask some now comments status.
